- Home
- Software Solutions
- Resources
- Corporate
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Sponsors:
| Phases:
| |
| Indications | Acronym: | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 21 | |
Additional information about NCT00287222.